These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Prospects: histone deacetylase inhibitors. Dokmanovic M; Marks PA J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937 [TBL] [Abstract][Full Text] [Related]
26. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation. Hutt DM; Roth DM; Marchal C; Bouchecareilh M Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814 [TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? Koutsounas I; Giaginis C; Theocharis S World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354 [TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors. Marks PA; Richon VM; Miller T; Kelly WK Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890 [TBL] [Abstract][Full Text] [Related]
29. Combination Therapies Targeting HDAC and IKK in Solid Tumors. Vancurova I; Uddin MM; Zou Y; Vancura A Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541 [TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. Budillon A; Di Gennaro E; Bruzzese F; Rocco M; Manzo G; Caraglia M Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):119-34. PubMed ID: 18221057 [TBL] [Abstract][Full Text] [Related]
31. The potential of histone deacetylase inhibitors in lung cancer. Aparicio A Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801 [TBL] [Abstract][Full Text] [Related]
32. Discovery and development of SAHA as an anticancer agent. Marks PA Oncogene; 2007 Feb; 26(9):1351-6. PubMed ID: 17322921 [TBL] [Abstract][Full Text] [Related]
33. Effects of novel HDAC inhibitors on urothelial carcinoma cells. Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501 [TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917 [TBL] [Abstract][Full Text] [Related]
35. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806 [TBL] [Abstract][Full Text] [Related]
36. [Histone-deacetylases inhibitors: from TSA to SAHA]. Peixoto P; Lansiaux A Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503 [TBL] [Abstract][Full Text] [Related]
37. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention. Ganai SA Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104 [TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Santini V; Gozzini A; Ferrari G Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226 [TBL] [Abstract][Full Text] [Related]